AXL antibodies

US8933202B2 · kind B2 · utility

Assignee

• U3 Pharma GmbH · DE

Inventors

• Thore Hettmann · Birkenfeld, DE
• Jens Niewöhner · Birkenfeld, DE
• Jens Ruhe · Martinsried, DE
• Peter Wirtz · Gauting, DE
• Kerstin SELLE · Pentenried, DE
• Esther Zwick-Wallasch · Birkenfeld, DE
• Mike Rothe · San Mateo, US

Key dates

• Filing date: Nov 12, 2008
• Grant date: Jan 13, 2015
• Expiry date: Jan 1, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.